Literature DB >> 29206656

HIV integration sites and implications for maintenance of the reservoir.

Jori Symons1, Paul U Cameron1,2, Sharon R Lewin1,2.   

Abstract

PURPOSE OF REVIEW: To provide an overview of recent research of how HIV integration relates to productive and latent infection and implications for cure strategies. RECENT
FINDINGS: How and where HIV integrates provides new insights into how HIV persists on antiretroviral therapy (ART). Clonal expansion of infected cells with the same integration site demonstrates that T-cell proliferation is an important factor in HIV persistence, however, the driver of proliferation remains unclear. Clones with identical integration sites harbouring defective provirus can accumulate in HIV-infected individuals on ART and defective proviruses can express RNA and produce protein. HIV integration sites differ in clonally expanded and nonexpanded cells and in latently and productively infected cells and this influences basal and inducible transcription. There is a growing number of cellular proteins that can alter the pattern of integration to favour latency. Understanding these pathways may identify new interventions to eliminate latently infected cells.
SUMMARY: Using advances in analysing HIV integration sites, T-cell proliferation of latently infected cells is thought to play a major role in HIV persistence. Clonal expansion has been demonstrated with both defective and intact viruses. Production of viral RNA and protein from defective viruses may play a role in driving chronic immune activation. The site of integration may determine the likelihood of proliferation and the degree of basal and induced transcription. Finally, host factors and gene expression at the time of infection may determine the integration site. Together these new insights may lead to novel approaches to elimination of latently infected cells.

Entities:  

Mesh:

Year:  2018        PMID: 29206656      PMCID: PMC5808998          DOI: 10.1097/COH.0000000000000438

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  56 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

Review 2.  Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

Authors:  Thomas A Rasmussen; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

3.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

5.  Nuclear architecture dictates HIV-1 integration site selection.

Authors:  Bruna Marini; Attila Kertesz-Farkas; Hashim Ali; Bojana Lucic; Kamil Lisek; Lara Manganaro; Sandor Pongor; Roberto Luzzati; Alessandra Recchia; Fulvio Mavilio; Mauro Giacca; Marina Lusic
Journal:  Nature       Date:  2015-03-02       Impact factor: 49.962

6.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

7.  Visualization of the intracellular behavior of HIV in living cells.

Authors:  David McDonald; Marie A Vodicka; Ginger Lucero; Tatyana M Svitkina; Gary G Borisy; Michael Emerman; Thomas J Hope
Journal:  J Cell Biol       Date:  2002-11-04       Impact factor: 10.539

8.  A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.

Authors:  Francesco Andrea Procopio; Rémi Fromentin; Deanna A Kulpa; Jessica H Brehm; Anne-Gaelle Bebin; Matthew C Strain; Douglas D Richman; Una O'Doherty; Sarah Palmer; Frederick M Hecht; Rebecca Hoh; Richard J O Barnard; Michael D Miller; Daria J Hazuda; Steven G Deeks; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  EBioMedicine       Date:  2015-06-27       Impact factor: 8.143

9.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013.

Authors:  Jing Wang; Dexter Duncan; Zhiao Shi; Bing Zhang
Journal:  Nucleic Acids Res       Date:  2013-05-23       Impact factor: 16.971

10.  LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes.

Authors:  Parmit Kumar Singh; Matthew R Plumb; Andrea L Ferris; James R Iben; Xiaolin Wu; Hind J Fadel; Brian T Luke; Caroline Esnault; Eric M Poeschla; Stephen H Hughes; Mamuka Kvaratskhelia; Henry L Levin
Journal:  Genes Dev       Date:  2015-11-01       Impact factor: 11.361

View more
  13 in total

1.  μ-Lat: A mouse model to evaluate human immunodeficiency virus eradication strategies.

Authors:  Hannah S Sperber; Padma Priya Togarrati; Kyle A Raymond; Mohamed S Bouzidi; Renata Gilfanova; Alan G Gutierrez; Marcus O Muench; Satish K Pillai
Journal:  FASEB J       Date:  2020-09-09       Impact factor: 5.191

Review 2.  CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.

Authors:  Gloria B Kim; Kristen Hege; James L Riley
Journal:  Front Immunol       Date:  2019-09-27       Impact factor: 7.561

Review 3.  Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy.

Authors:  Roland Schwarzer; Andrea Gramatica; Warner C Greene
Journal:  Viruses       Date:  2020-02-08       Impact factor: 5.048

Review 4.  Towards a Functional Cure of HIV-1: Insight Into the Chromatin Landscape of the Provirus.

Authors:  Julie Janssens; Anne Bruggemans; Frauke Christ; Zeger Debyser
Journal:  Front Microbiol       Date:  2021-03-18       Impact factor: 5.640

Review 5.  Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection.

Authors:  Chuen-Yen Lau; Matthew A Adan; Frank Maldarelli
Journal:  Viruses       Date:  2021-12-14       Impact factor: 5.048

6.  A prognostic risk model based on DNA methylation levels of genes and lncRNAs in lung squamous cell carcinoma.

Authors:  Weiqing Wang; Ming Xiang; Hui Liu; Xiao Chu; Zhaoyun Sun; Liang Feng
Journal:  PeerJ       Date:  2022-03-24       Impact factor: 2.984

Review 7.  Epigenetic crosstalk in chronic infection with HIV-1.

Authors:  Ulrike C Lange; Roxane Verdikt; Amina Ait-Ammar; Carine Van Lint
Journal:  Semin Immunopathol       Date:  2020-02-11       Impact factor: 9.623

Review 8.  The Impact of Cellular Proliferation on the HIV-1 Reservoir.

Authors:  Maria C Virgilio; Kathleen L Collins
Journal:  Viruses       Date:  2020-01-21       Impact factor: 5.048

Review 9.  Advances in Developing CAR T-Cell Therapy for HIV Cure.

Authors:  Jinxin Qi; Chengchao Ding; Xian Jiang; Yong Gao
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561

Review 10.  Block and Lock HIV Cure Strategies to Control the Latent Reservoir.

Authors:  Chantelle L Ahlenstiel; Geoff Symonds; Stephen J Kent; Anthony D Kelleher
Journal:  Front Cell Infect Microbiol       Date:  2020-08-14       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.